The report is published by the SET-C (Science in Emergencies Tasking: COVID-19) group at the Royal Society and it recommends a series of fundamental issues need to be addressed before a passport system could be introduced.
Of foremost concern is that any passport should reveal if the holder is protected from illness and unable to transmit the virus. Passports would also need to show vaccine efficacy, international acceptance and if it is effective against new or emerging variants. And passports would need to be secure, legal and ethical.
One of the report’s lead authors Professor Mills, Director of the Leverhulme Centre for Demographic Science, says, ‘Understanding what a vaccine passport could be used for is a fundamental question. Is it a passport to allow international travel or could it be used domestically to allow holders greater freedoms?
‘The intended use will have significant implications across a wide range of legal and ethical issues that need to be fully explored and could inadvertently discriminate or exacerbate existing inequalities.’
Understanding what a vaccine passport could be used for is a fundamental question...[It could] have significant implications across a wide range of legal and ethical issues
Professor Melinda Mills
Another lead author Professor Dye, Professor of Epidemiology in Oxford’s Department of Zoology, says, ‘An effective vaccine passport system that would allow the return to pre-COVID-19 activities, including travel, without compromising personal or public health, must meet a set of demanding criteria – but it is feasible.
‘First there is the science of immunity, then the challenges of something working across the world that is durable, reliable and secure. There are legal and ethical issues that need to be satisfied too.’
An effective vaccine passport system that would allow the return to pre-COVID-19 activities...without compromising personal or public health, must meet a set of demanding criteria – but it is feasible
Professor Chris Dye
Professor Mills adds, ‘International standardisation and following the lead of the WHO is one of the criteria we believe essential, but we have already seen some countries introducing vaccine certificates related to travel or linked to quarantine or attending events. We need a broader discussion about multiple aspects of a vaccine passport, from the science of immunity through to data privacy, technical challenges and the ethics and legality of how it might be used.’
Professor Dye maintains, ‘Huge progress has been made in many of these areas but we are not yet in the best position to use vaccine passports. At the most basic level, we are still gathering data on exactly how effective each vaccine is in preventing infection and transmission and on how long the immunity will last.’
We are not yet in the best position to use vaccine passports. At the most basic level, we are still gathering data on exactly how effective each vaccine is in preventing infection and transmission and on how long the immunity will last
The 12 criteria drawn up by the panel of experts are that a passport should:
- Meet benchmarks for COVID-19 immunity;
- Accommodate differences between vaccines in their efficacy, and changes in vaccine efficacy against emerging variants;
- Be internationally standardised
- Have verifiable credentials;
- Have defined uses;
- Be based on a platform of interoperable technologies;
- Be secure for personal data;
- Be portable;
- Be affordable to individuals and governments;
- Meet legal standards;
- Meet ethical standards;
- Have conditions of use that are understood and accepted by the passport holders.
The SET- C Steering Committee is composed of: Professor Peter Bruce FRS (Chair), The Royal Society; Professor Sir Roy Anderson FMedSci FRS, Imperial College; Professor Charles Bangham FMedSci FRS, Imperial College; Professor Richard Catlow FRS, The Royal Society; Professor Christopher Dye FMedSci FRS, University of Oxford; Professor Sir Marc Feldmann AC FAA FMedSci FRS; Professor Sir Colin Humphreys FREng FRS, Queen Mary University of London; Professor Frank Kelly FRS, University of Cambridge; Professor Melinda Mills FBA, University of Oxford; Professor Linda Partridge DBE FMedSci FRS, University College London; Professor Sir John Skehel FMedSci FRS, The Francis Crick Institute; Professor Geoffrey Smith FMedSci FRS, University of Cambridge and Professor Alain Townsend FRS, University of Oxford